Navigation Links
Gen-Probe Withdraws from Previously Announced Investor Presentations
Date:5/3/2012

SAN DIEGO, May 3, 2012 /PRNewswire/ -- Gen-Probe Incorporated (NASDAQ: GPRO) announced today that the Company has withdrawn from the following three upcoming investor conferences previously announced on April 26, 2012, and therefore will not webcast presentations at any of these investor conferences:

  • Deutsche Bank 37th Annual Health Care Conference in Boston on May 8 at 1:30 p.m. Eastern Time; 
  • Baird's 2012 Growth Stock Conference in Chicago on May 9 at 3:40 p.m. Central Time; and
  • Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas on May 15 at 4:20 p.m. Pacific Time.

(Logo:  http://photos.prnewswire.com/prnh/20120312/LA68580LOGO)

About Gen-Probe
Gen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to http://www.gen-probe.com.

Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions, or future events or performance are not historical facts and are forward-looking statements.  Forward-looking statements are not guarantees of performance.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our most recent Form 10-K, and all subsequent periodic filings.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contact:

Paula Izidoro
Investor Relations
858-410-8904


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
2. Gen-Probe to Webcast Presentation at the 30th Annual J.P. Morgan Healthcare Conference
3. Gen-Probe to Webcast Presentation at the Oppenheimer 22nd Annual Healthcare Conference
4. Gen-Probe Announces Webcast of Second Quarter 2011 Earnings Conference Call
5. Gen-Probe to Webcast Presentation at the William Blair & Company 31st Annual Growth Stock Conference
6. Gen-Probe Files for US Regulatory Clearance of PANTHER™ System, Fully Automated and Integrated Molecular Testing Instrument
7. Gen-Probe Reports Financial Results for the First Quarter of 2011
8. Gen-Probe to Webcast Three Upcoming Investor Presentations
9. Gen-Probe Announces $150 Million Stock Repurchase Plan
10. Gen-Probe to Webcast Two Upcoming Investor Presentations
11. Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2019)... ... November 22, 2019 , ... For the third year in a ... annual USGBC Greenbuild conference and expo in addition to showcasing a test installation of ... company’s Patcraft, Shaw Contract and Shaw Floors Builder Group brands. , Shaw offered five ...
(Date:11/23/2019)... (PRWEB) , ... November 23, 2019 , ... ... -- the number of birthdays we’ve celebrated -- has also broadly served as ... age isn’t the best way to make those assessments? , Researchers at the ...
(Date:11/22/2019)... ... November 22, 2019 , ... ... at Misch International Implant Institute. Completing this three-year program enhances Dr. Hogan’s expertise ... who are seeking permanent tooth replacement solutions. The Misch International Implant Institute has ...
Breaking Medicine Technology:
(Date:12/4/2019)... , ... December 04, 2019 , ... ... Opuntia Mesocarp Extract®, provides protection from disruptions to cells and tissue and inflammation ... menace of Jet Lag, is available in a dietary supplement product called ...
(Date:12/4/2019)... NEW YORK (PRWEB) , ... December 04, 2019 ... ... a Phase I study of AZD4041 for treating tobacco use and dependence. The ... is a central nervous system (CNS) penetrant antagonist of orexin-1 (hypocretin-1) receptors that ...
(Date:11/30/2019)... Texas (PRWEB) , ... November 28, 2019 , ... As ... may be the last such holiday for one of their loved ones. For those ... them to be home for the holiday season. , Spending their final months at ...
(Date:11/27/2019)... DIEGO (PRWEB) , ... November 27, 2019 , ... ... today announced that its cloud-based platform Nucleus.io has debuted major feature sets that ... This release will be shared with the public for the first time at ...
(Date:11/24/2019)... ... November 23, 2019 , ... At the 7th annual JADPRO ... presented the second annual Mary Pazdur Award for Excellence in Advanced Practice in ... Arizona. , Dr. Pelusi, a nurse practitioner, educator, and clinical trial sub-investigator with ...
Breaking Medicine News(10 mins):